Knight Reports First Quarter 2015 Results
MONTREAL, QUEBEC–(Marketwired – May 13, 2015) – Knight Therapeutics Inc. (TSX:GUD) (“Knight” or the “Company”), a leading Canadian specialty pharmaceutical company, today reported its first quarter ended March 31, 2015 financial results. First Quarter 2015 Highlights On January 1, 2015, Knight acquired NeurAxon Inc. (“NeurAxon”) for $1.75 million and amalgamated the company into Knight that […]
Knight Therapeutics to Present at the Bloom Burton & Co. Healthcare Investor Conference in Toronto
MONTREAL, QUEBEC–(Marketwired – Apr 28, 2015) – Knight Therapeutics Inc. (TSX:GUD) (“Knight” or the “Company”), a leading Canadian specialty pharmaceutical company, announced today that Mr. Jeffrey Kadanoff, CFO, is scheduled to present a corporate update at the Bloom Burton & Co. Healthcare Investor Conference on Monday, May 4, 2015 at 11:30 am ET at the […]
Knight Therapeutics Inc. Broadens Its Innovative Pharmaceutical Product Sourcing Strategy
MONTREAL, QUEBEC–(Marketwired – Apr 3, 2015) – Knight Therapeutics Inc. (TSX:GUD) (“Knight” or the “Company”), a leading Canadian specialty pharmaceutical company, announced today that it has committed to invest $10 million in HarbourVest Canada Growth Fund. L.P. (“HarbourVest Fund”). This investment is consistent with Knight’s strategy to leverage proven life science funds to help secure […]
Knight Therapeutics Participates in Secured Debt Offering
MONTREAL, QUEBEC–(Marketwired – Mar 31, 2015) – Knight Therapeutics Inc. (TSX:GUD) (“Knight” or the “Company”), a leading Canadian specialty pharmaceutical company, announced today that it has participated in the secured convertible debenture (“Debentures”) financing of Pediapharm Inc. (TSX VENTURE:PDP) (“Pediapharm”). Knight purchased $1.25 million of Debentures which bear interest at a rate of 12% per […]
Knight Therapeutics’ Secured Lending Strategy Validated by CRH Medical Corporation
MONTREAL, CANADA–(Marketwired – Mar 25, 2015) – Knight Therapeutics Inc. (TSX:GUD) (“Knight” or the “Company”), a leading Canadian specialty pharmaceutical company, announced today that it successfully helped finance CRH Medical Corporation’s (TSX:CRH) (OTCQX:CRMMF) (“CRH”) U.S. expansion as best evidenced by CRH’s recent equity offering: CRH raised $27.37 million of equity at $3.40 per share, more […]
Knight Reports Fourth Quarter and Year Ended December 31, 2014 Results
MONTREAL, QUEBEC–(Marketwired – Mar 19, 2015) – Knight Therapeutics Inc. (TSX:GUD) (“Knight” or the “Company”), a leading Canadian specialty pharmaceutical company, today reported financial results for its fourth quarter and year ended December 31, 2014. Highlights Knight committed to invest over $110 million into five life sciences funds. These funds (managed by Sectoral Asset Management […]
Notice of Knight Therapeutics’ Fourth Quarter and Year Ended December 31, 2014 Results Conference Call
MONTREAL, CANADA–(Marketwired – Mar 12, 2015) – Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, will release its fourth quarter and year ended December 31, 2014 financial results on Thursday, March 19, 2015 prior to the market opening. Following the release, Knight will hold a conference call at 8:30 a.m. (EST) hosted […]
Knight Therapeutics Inc. Signs Secured Debt Financing Agreement
MONTREAL, CANADA–(Marketwired – Jan 22, 2015) – Knight Therapeutics Inc. (TSX:GUD), through one of its wholly owned subsidiaries (“Knight”), announced today that it has entered into a senior secured debt financing agreement with Synergy Strips Corp. (OTCQB:SNYR) (“Synergy”), a US company focused on the health and wellness sector. The secured loan will fund Synergy’s acquisition […]
Knight Therapeutics Inc. Announces Board Change
MONTREAL, CANADA–(Marketwired – Jan 21, 2015) – Knight Therapeutics Inc. (TSX:GUD) (“Knight”) announced today (i) the resignation of Hillel Rosen and (ii) the appointment Ed Schutter to Knight’s Board of Directors. “Hillel will continue to provide legal counsel to Knight and its Board, and we thank him for his contributions to date,” said Jonathan Ross […]
Knight Therapeutics Inc. and NeurAxon Inc. Form Partnership for the Commercialization of NeurAxon’s Innovative Products
MONTREAL, QUEBEC–(Marketwired – Jan 1, 2015) – Knight Therapeutics Inc. (TSX:GUD) (“Knight” or the “Company”), a leading Canadian specialty pharmaceutical company, today announced that it has entered into a strategic partnership with NeurAxon Inc. (“NeurAxon”) for the commercialization of NeurAxon’s innovative products in various stages of development (“Pharmaceuticals”) in Canada, Israel, South Africa and Russia […]
